Demo day.

This pooled analysis of 3625 enrollees across four prospective trials receiving neoadjuvant chemo for locally-advanced esophageal cancer demonstrates that females, while clearly the minority (18%), suffered significantly more side effects but with nearly 25% less risk of recurrence or death. At the same time, patients over age 70 did just as well as their younger counterparts. | Athauda, Eur J Cancer 2020


Popular Posts